Biogen Completes Acquisition of Reata Pharmaceuticals

Written By Kathleen Otto

Biogen Inc. has successfully acquired Reata Pharmaceuticals, including SKYCLARYS® and other programs. The integration is expected to enhance Biogen's rare disease portfolio, with financial impact projections indicating slight dilution in 2023, neutrality in 2024, and significant accretion from 2025 onward, inclusive of transaction costs.

Kathleen Otto
Previous

Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
Next

Island Pharmaceuticals Readies for ISLA-101 Trial for Dengue Fever